Novo Nordisk Hit by an IT Security Breach: Pharma Giant Confronts Cyber Threats
Novo Nordisk (Novo Nordisk A/S) the Danish multinational pharmaceutical major, earlier this week announced that the company had identified an IT security incident involving unauthorised access to a limited number of internal IT...
FDA Grants Accelerated Approval to Sanofi’s Tzield® for Pediatric Stage 3 Type 1 Diabetes
The U.S. Food and Drug Administration has granted accelerated approval to Sanofi's Tzield® (teplizumab-mzwv) for children aged 8 to 17 years recently diagnosed with stage...
Orionis Biosciences Announces $1.44B Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines
Orionis Biosciences, a privately held, clinical-stage life sciences company pioneering proximity-induced therapeutic modalities, tl announced a multi-year collaboration with Novartis to discover and design molecular glue drugs...
Johnson & Johnson to acquire Firefly Bio to advance novel cancer treatment
Johnson & Johnson announced that it has entered into a definitive agreement to acquire Firefly Bio, Inc., a privately held biotechnology company specializing in...
Investors Show Strong Interest in Hexagon Nutrition IPO, Bids Reach 54 Times
Hexagon Nutrition Limited, a leading research-driven nutrition company, concluded its Initial Public Offering (IPO) with resounding success, achieving an overall subscription of 53.68 times...
AstraZeneca Advances Oral GLP-1 Elecoglipron to Phase III Programme
AstraZeneca announced positive results from the VISTA and SOLSTICE Phase IIb trials of elecoglipron, an investigational oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA). The data,...
